ClinicalTrials.gg
TerminatedNCT00813111Updated Jan 16, 2014Results posted

Phase 3 Study of Local Administration of SKY0402 for Postoperative Analgesia in Subject Undergoing Breast Augmentation

A Phase 3 interventional study of SKY0402 and Bupivacaine HCl in Pain, sponsored by Pacira Pharmaceuticals, Inc. Terminated at 15 sites in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-01-16.

Sponsored by Pacira Pharmaceuticals, Inc · Phase 3, Interventional, and Supportive care

Why this study was terminated
Sponsor decision, unrelated to safety

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
136
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 146 studies testing bupivacaine in Pain — 19 open to participants now, 19 under way, 3 of them phase 3. Bupivacaine · Pain.

Enrollment
21st of 146
136 · median 63
Started
2008
with 7 others
Phase 3
17 of 146
1 open now
Registered
14th of 146
by date
Lead sponsor
16 of 146
Pacira Pharmaceuticals, Inc

Among the 146 studies testing bupivacaine in Pain, this one is the 21st largest by enrollment, is one of 8 that started in 2008, is one of 17 in phase 3, and was the 14th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,651 are open to participants now.

Browse Pain studies →

Open to participants now

19 of the 146 studies testing bupivacaine in Pain are open now, in 5 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

About bupivacaine

Bupivacaine: first FDA approval 1972 (MARCAINE HYDROCHLORIDE PRESERVATIVE FREE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 928 Pain studies recruiting now, 383 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 222 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 146 studies testing bupivacaine in Pain, or all of them as a file.
02

Study summary

The purpose of this study is to provide a more effective postoperative method of pain control for patients undergoing cosmetic sub-muscular breast augmentation. Appropriate postoperative pain management contributes to faster patient mobilization, shortened hospital stays, and reduced healthcare costs.

Read the detailed description

This is a phase 3 study conducted to evaluate the safety and efficacy of a single local administration of 300 mg of SKY0402 compared with 100 mg of conventional, commercially-available bupivacaine HCl (i.e. Marcaine 0.5% with epinephrine) administered locally into the implant pocket of each breast for postoperative analgesia in subjects undergoing bilateral, cosmetic, sub-muscular, breast augmentation under general anesthesia (endotracheal or otherwise). A total of 600 mg of SKY0402 or 200 mg bupivacaine HCl per subject is therefore administered. Post-operative assessments were conducted including adverse event and serious adverse event monitoring through Day 30.

03

Conditions studied

  • Pain

Keywords

  • Postsurgical pain
  • Analgesia
  • Breast augmentation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Women greater than or equal to 18 years of age at Screening Visit
  2. , surgically sterile, or willing to use acceptable means of for at least 30 days after surgery including any of the following: hormonal contraceptives (e.g., oral, injectable, implantable starting at least 30 days before study administration), effective double-barrier methods (e.g., condoms with spermicide), intrauterine device, lifestyle with a personal choice of abstinence, nonheterosexual lifestyle, or a strictly monogamous relationship with a partner who has had a vasectomy.
  3. Scheduled to undergo primary, bilateral, cosmetic, sub-muscular, breast augmentation under general anesthesia (endotracheal or otherwise)
  4. (ASA) Physical Class 1-4
  5. Able and willing to comply with all study visits and procedures, and with diary entries through postoperative day 8
  6. Able to speak, read, and understand the language of the form (ICF), study questionnaires, and other instruments used for collecting subject-reported outcomes, in order to enable accurate and appropriate responses to pain scales and other required study assessments
  7. Willing and capable of providing written informed consent.

Exclusion criteria

Exclusion Criteria:

A subject will not be eligible for the study if she meets any of the following criteria:

  1. Women undergoing reconstructive surgery following mastectomy
  2. Pregnancy, nursing, or planning to become pregnant during the study or within one month after study drug administration.
  3. Use of any of the following medications within the times specified before surgery:

    1. long-acting opioids within 3 days.
    2. Any opioid medication within 24 hours.
  4. Concurrent painful physical condition or concurrent surgery that may require analgesic treatment in the postoperative period for pain that is not strictly related to the surgical site being administered study drug (e.g., significant pain from other joints, chronic neuropathic pain, concurrent abdominal surgery, etc.), which have the potential to confound the postoperative study assessments.
  5. Body weight less than 50 kilograms (110 pounds)
  6. History of or idiosyncratic reaction to amide-type local anesthetics, opioid medication, epinephrine, or sulfites.
  7. to epinephrine, such as concurrent administration of ergot-type drugs, monoamine oxidase (MAO) inhibitors or antidepressants of tryptoline or imipramine types, conditions where the production or exacerbation of tachycardia could provide fatal (e.g., poorly controlled thyrotoxicosis or severe heart disease) or any other pathological conditions that might be aggravated by the effect of epinephrine.
  8. Administration of product within 30 days of 5 elimination half-lives of such investigational product, whichever is longer, prior to study drug administration or planned administration of another investigational product or procedure during the subject's participation in this study.
  9. History of, suspected, or known addiction to or abuse of illicit drug(s), prescription medicine(s), or alcohol within the past 2 years.
  10. Uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the opinion of the investigator, may interfere with study assessments or compliance with the protocol.
  11. Significant medical conditions or laboratory results that, in the opinion of the Investigator, indicate an increased vulnerability to study drugs and procedures, and expose the subject to an unreasonable risk as a result of participating in this clinical trial, such as: debilitating diseases, acute illnesses, hypotension, partial or complete conduction block, impaired cardiac function, untreated hypertension, advanced arteriosclerotic heart disease, cerebral vascular insufficiency, pre-existing abnormal neurological or neuromuscular disease (e.g., epilepsy, myasthenia gravis), advanced liver disease, severe renal impairment, advanced diabetes, co-morbid conditions associated with an status such as blood dyscrasias, /AIDS, or recent chemotherapy.

    In addition, the subject will be ineligible to receive study drug if she meets the following criteria during surgery:

  12. Any event or condition uncovered during the surgery (e.g., excessive bleeding, acute sepsis) that might render the subject medically unstable or complicate the subject's postoperative course.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Care provider, Investigator)
Enrollment
136 participants (actual)

Study arms

  • Experimental
    SKY0402

    A single local administration of 300 mg in a 20-mL volume into each breast implant pocket for a total dose of 600 mg (i.e., a total of 40 mL)

    Drug: SKY0402

  • Active comparator
    Bupivacaine HCl

    A single local administration of 100 mg in a 20-mL volume into each breast implant pocket for a total dose of 200 mg (i.e., a total of 40 mL)

    Drug: Bupivacaine HCl

Interventions

  • 600mg SKY0402 instilled into breast pocket during surgery

    Also known as: EXPAREL

  • 200mg Bupivacaine HCl instilled into breast pocket during surgery

    Also known as: Marcaine 0.5% with epinephrine

06

What researchers measure

Primary outcomes

  1. Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) With Activity (NRS-A) Pain Intensity Scores

    Assessments of postoperative pain included pain intensity at rest (using the NRS at rest \[NRS-R\] and with activity \[using the NRS-A\]) where the prescribed activity was raising both arms. Pain intensity was assessed on a scale of 0 to 10, where 0=no pain and 10=worst possible pain.

    Time frame: through 72 hours

Secondary outcomes

  1. Number of Participants With Adverse Events

    Time frame: 30 days

07

Results

Posted Jan 16, 2014

Participant flow

Participant flow — Overall Study
MilestoneSKY0402Bupivacaine HCl
Started6670
Completed6470
Not completed20

Outcome measures

PrimaryArea Under the Curve (AUC) of the Numeric Rating Scale (NRS) With Activity (NRS-A) Pain Intensity Scores

Assessments of postoperative pain included pain intensity at rest (using the NRS at rest \[NRS-R\] and with activity \[using the NRS-A\]) where the prescribed activity was raising both arms. Pain intensity was assessed on a scale of 0 to 10, where 0=no pain and 10=worst possible pain.

Time frame:
through 72 hours
Reported as:
Mean · Units on a scale*hours
Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) With Activity (NRS-A) Pain Intensity Scores
Units on a scale*hoursSKY0402Bupivacaine HCl
Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) With Activity (NRS-A) Pain Intensity Scores441 ± 163467 ± 181
SecondaryNumber of Participants With Adverse Events
Time frame:
30 days

Results for this outcome have not been posted.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SKY0402—0/64 (0%)48/66 (72.7%)
Bupivacaine HCl—0/70 (0%)51/70 (72.9%)
Most frequent other events
Most frequent other events
EventSKY0402Bupivacaine HCl
nauseaGastrointestinal disorders29/6637/70
vomitingGastrointestinal disorders10/6614/70
ConstipationGastrointestinal disorders11/6613/70
Muscle SpasmsMusculoskeletal and connective tissue disorders10/6611/70
TachycardiaCardiac disorders3/667/70
MyalgiaMusculoskeletal and connective tissue disorders6/660/70
InsomniaPsychiatric disorders6/664/70
HeadacheNervous system disorders2/665/70
ChillsGeneral disorders4/662/70
HypoaesthesiaNervous system disorders4/663/70

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)SKY0402Bupivacaine HClTotal
<=18 years000
Between 18 and 65 years6670136
>=65 years000
Age, Continuous
Age, Continuous(years)SKY0402Bupivacaine HClTotal
Mean30.8 ± 7.330.6 ± 7.630.7 ± 7.4
Sex: Female, Male
Sex: Female, Male(Participants)SKY0402Bupivacaine HClTotal
Female6670136
Male000
Region of Enrollment
Region of Enrollment(participants)SKY0402Bupivacaine HClTotal
United States6670136
08

Study locations

15 sites
  • West Alabama Research, LLC.
    Birmingham, Alabama 35209, United States
  • West Alabama Research, LLC
    Birmingham, Alabama 35209, United States
  • Horizon Research Group, Inc
    Mobile, Alabama 36608, United States
  • La Jolla Spa MD
    La Jolla, California 90237, United States
  • Associates for Plastic Surgery Medical Group, Inc.
    La Jolla, California 92037, United States
  • Lotus Clinical Research
    Pasadena, California 91105, United States
  • Pacific Plastic Surgery
    Santa Barbara, California 93105, United States
  • Miami Plastic Surgery
    Miami, Florida 33176, United States
  • North Fulton Plastic Surgery
    Roswell, Georgia 30076, United States
  • Waldman and Schantz Plastic Surgery
    Lexington, Kentucky 40508, United States
  • Back Bay Plastic Surgery
    Boston, Massachusetts 02116, United States
  • Personal Enhancement Center
    Toms River, New Jersey 08753, United States
  • The Ohio State University Research Foundation
    Columbus, Ohio 43210, United States
  • Research Concepts, Ltd
    Bellaire, Texas 77402, United States
  • Office of Dr. William P. Adams, Jr., MD
    University Park, Texas 75205, United States
09

References and documents

Publications

  • Dasta J, Ramamoorthy S, Patou G, Sinatra R. Bupivacaine liposome injectable suspension compared with bupivacaine HCl for the reduction of opioid burden in the postsurgical setting. Curr Med Res Opin. 2012 Oct;28(10):1609-15. doi: 10.1185/03007995.2012.721760. Epub 2012 Sep 3. PubMed 22900785 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2008, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2014, 4 years 11 months after primary completion. A results delay was requested in Aug 2010.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2008
First posted
Dec 22, 2008
Start
Nov 2008
Primary completionActual
Feb 2009
CompletionActual
Feb 2009
Results delay requested
Aug 25, 2010
Results first posted
Jan 16, 2014
Last update
Jan 16, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00813111
Responsible party
Sponsor
First posted
Dec 22, 2008
Start date
Nov 2008
Primary completion
Feb 2009
Completion
Feb 2009
Results posted
Jan 16, 2014
Last update
Jan 16, 2014

Study contacts

Kay Warnott, RN
study director · Pacira Pharmaceuticals, Inc

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bupivacaine

Start the discussion